Profits At Top 10 Listed Biopharmaceutical Firms In Shanghai And Shenzhen Up 40 Percent
This article was originally published in PharmAsia News
Executive SummaryAccording to the "Shanghai, Shenzhen 500 Performance Predictions 2010" report jointly released by Sohu Finance and Wistrategy Consulting, the top 10 listed biopharmaceutical companies will secure 15.7 and 40.4 percent growth in operating income and net profits, respectively
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.